Starting November 26, Community Medical Center’s Main Entrance will be closed for Main Lobby renovations.

Research Trials

Along with our established reputation for world-class renal and pancreas transplant, our Department of Transplant Research continues to participate in clinical drug trials and investigate the most current anti-rejection medications available. To follow are our current studies.

  • Angion “BB3” Biomedica
    Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney. The Renal and Pancreas Transplant Division is proud to offer kidney transplant recipients access to the latest and most advanced treatment options.
    Trial is open for enrollment with Dr. Praveen Kandula as site Principal Investigator.
    For more information, please call Ana Merced-Castro, RN, BSN, CCTC, at 973-322-8467 or Johanne Felix RN, BSN at 973-322-8466.
  • Merck MK 8228
    A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir (LET)) versus Valganciclovir (VGCV) for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients. The Renal and Pancreas Transplant Division is proud to offer kidney transplant recipients access to the latest and most advanced treatment options.
    Trial is open for enrollment with Dr. Anup Patel as site Principal Investigator.
    For more information, please call Ana Merced-Castro, RN, BSN, CCTC, at 973-322-8467 or Johanne Felix RN, BSN at 973-322-8466.
  • CSL” SCL (C1-esterase inhibitor, human)
    A Double-Blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor as Add-On to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients. The Renal and Pancreas Transplant Division is proud to offer kidney transplant recipients access to the latest and most advanced treatment options.
    Trial is open for enrollment with Dr. Anup Patel as site Principal Investigator.
    For more information, please call Ana Merced-Castro, RN, BSN, CCTC, at 973-322-8467 or Johanne Felix RN, BSN at 973-322-8466.